BioLife Solutions posts Q2 2026 results as Repligen acquisition heads toward Q4 close

BioLife Solutions announced second quarter 2026 results on August 6, 2026, against the backdrop of its pending acquisition by Repligen. On July 21, 2026, BioLife entered into a definitive agreement under which Repligen will acquire BioLife for a total enterprise value of approximately $1.5 billion, structured as $11.25 in cash plus 0.1442 shares of Repligen common stock per BioLife share, subject to customary closing conditions.¹ Once the merger closes, BioLife will stop trading publicly; the deal is expected to close in the fourth quarter of 2026, pending stockholder approval, regulatory clearance, and other closing conditions.¹ Because of the pending deal, BioLife will not be hosting a conference call.¹

On the operating side, the company highlighted its position in the cell and gene therapy supply chain. Its biopreservation media is used in roughly 250 ongoing commercially sponsored clinical trials in the U.S., representing more than 70% market share, including over 30 Phase III trials, or nearly 80% of late-stage trials in this category; its CellSeal vials and human platelet lysate (hPL) products are used in more than 35 clinical trials.¹ As of June 30, 2026, its biopreservation media was embedded in 18 approved cell and gene therapies, with the company expecting approvals, expansions, or new indications for 8 additional products over the next 12 months; its CellSeal vials and hPL products are embedded in four approved therapies.¹

Financially, total revenue for the quarter was $28.5 million, up 21% over the second quarter of 2025, with GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65%.¹ GAAP net income was $45.1 million, which included a $42.4 million non-cash income tax benefit, while non-GAAP adjusted EBITDA was $7.4 million, or 26% of revenue.¹ Cash, cash equivalents, and marketable securities stood at $113.1 million as of June 30, 2026.¹